Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies

V. Sandecka, T. Popkova, M. Stork, V. Maisnar, J. Minarik, A. Jungova, P. Pavlicek, L. Stejskal, L. Pospisilova, A. Heindorfer, J. Obernauerova, E. Gregora, M. Sykora, J. Ullrychova, M. Wrobel, P. Kessler, T. Jelinek, P. Kunovszki, S. Bathija, B....

. 2023 ; 13 (1) : 153. [pub] 20230927

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016182

Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20/2/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG). Key outcomes included progression-free survival from SMM diagnosis to active MM diagnosis or death (PFS), progression-free survival from SMM diagnosis to progression on first line (1 L) MM treatment or death (PFS2), and overall survival (OS). Of 498 patients, 174 (34.9%) were classified as high risk and 324 (65.1%) as non-high risk. Median follow-up was approximately 65 months. During follow-up, more patients in the high-risk vs non-high-risk group received 1 L MM treatment (76.4% vs 46.6%, p < 0.001). PFS, PFS2, and OS were significantly shorter in high-risk vs non-high-risk patients (13.2 vs 56.6 months, p < 0.001; 49.9 vs 84.9 months, p < 0.001; 93.2 vs 131.1 months, p = 0.012, respectively). The results of this study add to the growing body of evidence that patients with high-risk vs non-high-risk SMM have significantly worse outcomes, including OS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016182
003      
CZ-PrNML
005      
20231026110233.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-023-00906-7 $2 doi
035    __
$a (PubMed)37752128
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sandecka, Viera $u University Hospital Brno, Brno, Czech Republic
245    10
$a Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies / $c V. Sandecka, T. Popkova, M. Stork, V. Maisnar, J. Minarik, A. Jungova, P. Pavlicek, L. Stejskal, L. Pospisilova, A. Heindorfer, J. Obernauerova, E. Gregora, M. Sykora, J. Ullrychova, M. Wrobel, P. Kessler, T. Jelinek, P. Kunovszki, S. Bathija, B. Gros, S. Wilbertz, Q. Cai, A. Lam, I. Spicka
520    9_
$a Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20/2/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG). Key outcomes included progression-free survival from SMM diagnosis to active MM diagnosis or death (PFS), progression-free survival from SMM diagnosis to progression on first line (1 L) MM treatment or death (PFS2), and overall survival (OS). Of 498 patients, 174 (34.9%) were classified as high risk and 324 (65.1%) as non-high risk. Median follow-up was approximately 65 months. During follow-up, more patients in the high-risk vs non-high-risk group received 1 L MM treatment (76.4% vs 46.6%, p < 0.001). PFS, PFS2, and OS were significantly shorter in high-risk vs non-high-risk patients (13.2 vs 56.6 months, p < 0.001; 49.9 vs 84.9 months, p < 0.001; 93.2 vs 131.1 months, p = 0.012, respectively). The results of this study add to the growing body of evidence that patients with high-risk vs non-high-risk SMM have significantly worse outcomes, including OS.
650    _2
$a lidé $7 D006801
650    12
$a doutnající mnohočetný myelom $x diagnóza $x epidemiologie $x terapie $7 D000075122
650    12
$a mnohočetný myelom $x diagnóza $x epidemiologie $x terapie $7 D009101
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a registrace $7 D012042
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Popkova, Tereza $u University Hospital Ostrava and Faculty of Medicine, Ostrava, Czech Republic
700    1_
$a Stork, Martin $u University Hospital Brno, Brno, Czech Republic
700    1_
$a Maisnar, Vladimir $u Charles University Hospital and Faculty of Medicine Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Minarik, Jiri $u University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Jungova, Alexandra $u University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Pavlicek, Petr $u University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Stejskal, Lukas $u Silesian Hospital in Opava, Opava, Czech Republic
700    1_
$a Pospisilova, Lenka $u Institute of Biostatistics and Analyses Ltd, Brno, Czech Republic
700    1_
$a Heindorfer, Adriana $u Liberec Regional Hospital, Liberec, Czech Republic
700    1_
$a Obernauerova, Jarmila $u Regional Hospital Mlada Boleslav, Mlada Boleslav, Czech Republic
700    1_
$a Gregora, Evzen $u Motol University Hospital, Prague, Czech Republic
700    1_
$a Sykora, Michal $u Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
700    1_
$a Ullrychova, Jana $u KZ, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic
700    1_
$a Wrobel, Marek $u Hospital Novy Jicin, Novy Jicin, Czech Republic
700    1_
$a Kessler, Petr $u Hospital Pelhrimov, Pelhrimov, Czech Republic
700    1_
$a Jelinek, Tomas $u University Hospital Ostrava and Faculty of Medicine, Ostrava, Czech Republic $1 https://orcid.org/0000000254679253
700    1_
$a Kunovszki, Peter $u Janssen Global Services, Budapest, Hungary
700    1_
$a Bathija, Sacheeta $u Janssen Global Services, Raritan, NJ, USA
700    1_
$a Gros, Blanca $u Janssen-Cilag, Madrid, Spain
700    1_
$a Wilbertz, Sabine $u Janssen-Cilag GmbH, Neuss, Germany
700    1_
$a Cai, Qian $u Janssen Global Services, Titusville, NJ, USA
700    1_
$a Lam, Annette $u Janssen Global Services, Raritan, NJ, USA
700    1_
$a Spicka, Ivan $u Charles University and General Hospital in Prague, Prague, Czech Republic. spicka@cesnet.cz $1 https://orcid.org/0000000254515283 $7 jn20001103644
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 13, č. 1 (2023), s. 153
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37752128 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110227 $b ABA008
999    __
$a ok $b bmc $g 1999986 $s 1202544
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 1 $d 153 $e 20230927 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace